bluebird bio, Inc. (BLUE) Hits New 1-Year High at $165.28

bluebird bio, Inc. (NASDAQ:BLUE) hit a new 52-week high on Monday . The stock traded as high as $165.28 and last traded at $163.20, with a volume of 483000 shares traded. The stock had previously closed at $160.15.

Several brokerages have weighed in on BLUE. BidaskClub raised bluebird bio from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Morgan Stanley reaffirmed a “hold” rating on shares of bluebird bio in a research report on Wednesday, August 9th. Maxim Group set a $170.00 target price on bluebird bio and gave the stock a “buy” rating in a research report on Friday. Leerink Swann reaffirmed an “outperform” rating and issued a $120.00 target price on shares of bluebird bio in a research report on Saturday, September 30th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $88.00 target price on shares of bluebird bio in a research report on Friday, August 11th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. bluebird bio has an average rating of “Buy” and a consensus target price of $131.05.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The company had revenue of $7.71 million during the quarter, compared to analyst estimates of $8.47 million. During the same quarter last year, the business earned ($2.07) EPS. The company’s revenue for the quarter was up 397.4% compared to the same quarter last year. sell-side analysts forecast that bluebird bio, Inc. will post -6.68 EPS for the current year.

In related news, insider Jeffrey T. Walsh sold 9,900 shares of the stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $149.58, for a total value of $1,480,842.00. Following the completion of the sale, the insider now directly owns 28,798 shares of the company’s stock, valued at approximately $4,307,604.84. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Nick Leschly sold 46,833 shares of the stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $122.27, for a total value of $5,726,270.91. Following the completion of the sale, the insider now directly owns 289,368 shares of the company’s stock, valued at $35,381,025.36. The disclosure for this sale can be found here. Insiders sold a total of 193,168 shares of company stock valued at $25,558,003 in the last quarter. 3.90% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the stock. Hanseatic Management Services Inc. lifted its stake in bluebird bio by 0.3% in the 2nd quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock worth $1,096,000 after acquiring an additional 27 shares in the last quarter. Teacher Retirement System of Texas lifted its stake in bluebird bio by 1.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 53 shares in the last quarter. Cornerstone Capital Management Holdings LLC. lifted its stake in bluebird bio by 0.8% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock worth $1,885,000 after acquiring an additional 140 shares in the last quarter. Prudential Financial Inc. lifted its stake in bluebird bio by 4.0% in the 2nd quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock worth $408,000 after acquiring an additional 150 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in bluebird bio by 0.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock worth $3,302,000 after acquiring an additional 151 shares in the last quarter.

WARNING: “bluebird bio, Inc. (BLUE) Hits New 1-Year High at $165.28” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.com-unik.info/2017/11/20/bluebird-bio-inc-blue-hits-new-1-year-high-at-165-28.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

What are top analysts saying about bluebird bio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for bluebird bio Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit